SAB Biotherapeutics, Inc. (SABS) Financials

SAB Biotherapeutics, Inc. (SABS) reported diluted earnings per share of -$0.79 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

SAB Biotherapeutics, Inc. (SABS) had EBITDA of -$46.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

SAB Biotherapeutics, Inc. (SABS) has a return on equity of 8.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

SAB Biotherapeutics, Inc. (SABS) recorded an outflow of $45.7M in free cash flow during fiscal year 2025. This represents a -32.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

SAB Biotherapeutics, Inc. (SABS) recorded an outflow of $44.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

SAB Biotherapeutics, Inc. (SABS) had $172.8M in total assets as of fiscal year 2025, including both current and long-term assets.

SAB Biotherapeutics, Inc. (SABS) invested $933K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

SAB Biotherapeutics, Inc. (SABS) invested $34.4M in research and development during fiscal year 2025.

SAB Biotherapeutics, Inc. (SABS) had 51M shares outstanding as of fiscal year 2025.

SAB Biotherapeutics, Inc. (SABS) had a current ratio of 9.46 as of fiscal year 2025, which is generally considered healthy.

SAB Biotherapeutics, Inc. (SABS) had a debt-to-equity ratio of 0.14 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

SAB Biotherapeutics, Inc. (SABS) had a return on assets of 7.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

SAB Biotherapeutics, Inc. (SABS) trades at 20.4x earnings, its market capitalization divided by net income of $13.3M net income, FY2025. The market capitalization is $271.1M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

SAB Biotherapeutics, Inc. (SABS) has no price-to-sales ratio at the moment: revenue is not positive (FY2025). The market capitalization is $271.1M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, SAB Biotherapeutics, Inc. (SABS) held $143.5M in cash, cash equivalents and investments, and reported an operating cash outflow of $44.8M over that year. Dividing the one by the other, the reported balance equals about 38 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

SAB Biotherapeutics, Inc. (SABS) has an Altman Z-Score of 6.43, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

SAB Biotherapeutics, Inc. (SABS) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

For every $1 of reported earnings, SAB Biotherapeutics, Inc. (SABS) used $3.37 of operating cash (-$44.8M OCF vs $13.3M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

SAB Biotherapeutics, Inc. (SABS) reported an operating loss of $49.0M against $241K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.